Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
NuCana plc Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.	United States of America	NCNA
NUFORMIX PLC Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.	United Kingdom	NFX
Nurix Therapeutics, Inc. Developing protein degradation medicines to treat cancer and autoimmune diseases.	United States of America	NRIX
NUTEX Investments Plc Develops & distributes health, cosmetic & pharma products from natural ingredients globally.	Hungary	NUTEX
NutriBand Inc. Develops abuse-deterrent transdermal patches to make potent drug delivery safer.	United States of America	NTRB
Nuvalent, Inc. Designs targeted small molecule drugs for kinase-driven cancers to overcome treatment resistance.	United States of America	NUVL
Nuvation Bio Inc. A clinical-stage biopharma developing novel drugs for difficult-to-treat cancers.	United States of America	NUVB
Nxera Pharma Co., Ltd. Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.	Japan	4565
ObsEva SA Developed novel therapeutics for women's reproductive health and pregnancy.	Switzerland	OBSN
OCULAR THERAPEUTIX, INC Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.	United States of America	OCUL